Advertisement
Canada markets open in 5 hours 29 minutes

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7274
    +0.0010 (+0.14%)
     

  • CRUDE OIL

    83.68
    +0.95 (+1.15%)
     

  • Bitcoin CAD

    88,784.15
    +4,654.82 (+5.53%)
     

  • CMC Crypto 200

    1,326.78
    +14.15 (+1.08%)
     

  • GOLD FUTURES

    2,403.80
    +5.80 (+0.24%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     

  • NASDAQ futures

    17,429.25
    -118.00 (-0.67%)
     

  • VOLATILITY

    20.70
    +2.70 (+15.00%)
     

  • FTSE

    7,829.22
    -47.83 (-0.61%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Why Amryt Pharma (AMYT) Might Surprise This Earnings Season

Zacks Equity Research
·2 min read

Investors are always looking for stocks that are poised to beat at earnings season and Amryt Pharma plc AMYT may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Amryt Pharma is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for AMYT in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 9 cents per share for AMYT, compared to a broader Zacks Consensus Estimate of a loss of 14 cents per share. This suggests that analysts have very recently bumped up their estimates for AMYT, giving the stock a Zacks Earnings ESP of +33.33% heading into earnings season.

Amryt Pharma PLC Sponsored ADR Price and EPS Surprise

Amryt Pharma PLC Sponsored ADR Price and EPS Surprise
Amryt Pharma PLC Sponsored ADR Price and EPS Surprise

Amryt Pharma PLC Sponsored ADR price-eps-surprise | Amryt Pharma PLC Sponsored ADR Quote

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

ADVERTISEMENT

Given that AMYT has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for Amryt Pharma and that a beat might be in the cards for the upcoming report.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Amryt Pharma PLC Sponsored ADR (AMYT) : Free Stock Analysis Report

To read this article on Zacks.com click here.